This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kronenfeld, J. J. Articles by Russell, R. O. Search for Related Content PubMed PubMed Citation Articles by Kronenfeld, J. J. Articles by Russell, R. O., Jr

Circulation, Vol 60, 16-22, Copyright © 1979 by American Heart Association

ARTICLES

Unstable angina pectoris: an examination of modes and costs of therapy

JJ Kronenfeld, ED Charles Jr, JB Wayne, A Oberman, NT Kouchoukos, WJ Rogers, JA Mantle, CE Rackley and RO Russell Jr

Debate exists over the most appropriate form of treatment for patients with unstable angina pectoris. This study examined 106 patients randomized at the University of Alabama in Birmingham as part of the National Cooperative Study Group and focuses on the phenomenon of patients who fail medical therapy and thus require late surgery, and the costs of therapy. Discriminant function analysis revealed that the significant predictors (p less than 0.01) of patients who would later require surgery were: total number of vessels diseased, angina severly, presence of congestive heart failure, hypertension, and number of years that the patient had had angina. By means of this analysis, 85% of the late surgery patients were correctly predicted. Late surgery patients averaged 2.4 diseased vessels vs 1.5 for persistent medical patients (p less than 0.01). Mean charges for the first 2 years in the study were $6,226 (SD $2,967) for persistent medical patients, $10,416 (SD $2,146) for surgery patients, and $20,059 (SD $10,748) for late surgery patients (p less than 0.001). These data indicate that surgery is clearly an expensive procedure; but that it is more expensive for late surgery patients, who have total costs that are twice as high as surgical costs and 3.5 times as high as persistent medical costs.

This article has been cited by other articles:

				E. B. LEAHEY JR Digoxin-Quinidine Interaction: Current Status Ann Intern Med, November 1, 1980; 93(5): 775 - 776. [Abstract] [PDF]